{"id":40086,"date":"2026-11-16T10:59:00","date_gmt":"2026-11-16T15:59:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=40086"},"modified":"2026-11-03T08:34:29","modified_gmt":"2026-11-03T13:34:29","slug":"the-ftc-doesnt-care-how-many-patents-youve-listed-it-cares-whether-one-of-them-is-real","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-ftc-doesnt-care-how-many-patents-youve-listed-it-cares-whether-one-of-them-is-real\/","title":{"rendered":"The FTC Doesn&#8217;t Care How Many Patents You&#8217;ve Listed. It Cares Whether One of Them Is Real."},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/11\/image-6.png\" alt=\"\" class=\"wp-image-40087\" srcset=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/11\/image-6.png 1024w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/11\/image-6-300x168.png 300w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/11\/image-6-768x429.png 768w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">On December 10, 2025, the Federal Trade Commission announced that Teva had asked the FDA to remove more than 200 patent listings from the Orange Book. The listings covered more than 30 products for asthma, diabetes and COPD, plus epinephrine autoinjectors. [1]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FTC Chairman Andrew Ferguson said that when improper patent listings limit competition from generic alternatives, &#8220;it hurts Americans&#8217; bank accounts.&#8221; [1] The key word is &#8220;improper.&#8221; The agency did not object to the size of Teva&#8217;s portfolio. Its letters name patents one at a time and test each one against the statute. [2] [3]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The test is short. A patent belongs in the Orange Book only if it claims the drug or a method of using the drug. [4] A portfolio of twenty listed patents can pass that test. One listed patent can fail it, and that one failure can hold back generic approval for 30 months. [5]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This article explains the test, the 2023 to 2025 enforcement record, and the court decisions behind it. It also gives a screening method for teams that rely on Orange Book dates. DrugPatentWatch tracks Orange Book listings and delistings by drug. It is a good index for the first pass. The claim text and the court record are the evidence.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Short Answer: What the FTC Tests When It Reads an Orange Book Entry<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The FTC tests each listed patent against its claims. It asks whether the patent claims the drug or a method of using the drug. [4] The number of listings is not the test.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What does &#8220;claims the drug&#8221; mean for an Orange Book listing?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A patent claims the drug when it &#8220;particularly points out and distinctly claims the drug.&#8221; For a product patent, the Federal Circuit held that this means the patent must claim at least the active ingredient. [6]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>The statutory text<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Congress set the rule in the Orange Book Transparency Act, enacted on January 5, 2021. [7] An NDA holder must submit each patent that claims the drug as a drug substance or drug product patent. It must also submit each patent that claims a method of using the drug. [7]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The patent must be one for which &#8220;a claim of patent infringement could reasonably be asserted.&#8221; [7] The Act also says that patent information of any other type &#8220;shall not be submitted.&#8221; [7]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FDA regulations name four patent types that an NDA must not include: process, packaging, metabolite and intermediate patents. [5]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>What the Federal Circuit added in Teva v. Amneal<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The court wrote: &#8220;To claim that drug, the patent must claim at least the active ingredient.&#8221; [6] It also held that patents claiming just the device components of an approved product &#8220;do not meet the listing requirement.&#8221; [6]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The court rejected Teva&#8217;s argument that &#8220;claims&#8221; means &#8220;could be infringed.&#8221; In its words, &#8220;the fact that an NDA could infringe a patent does not mean that the patent &#8216;claims&#8217; the underlying drug.&#8221; [6]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why a long patent list does not trigger the FTC test, and why one bad entry can<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A generic applicant must address each listed patent. If the brand sues on a listed patent after a Paragraph IV challenge, a 30-month stay blocks FDA approval of the generic unless a court decides the dispute sooner. [5]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FTC says the stay applies &#8220;regardless of whether a court ultimately finds the patent at issue is valid or infringed by the competing product.&#8221; [4] The unit of harm is therefore the single listed patent that supports a suit. It is not the size of the list.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Eight Findings That Matter<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Each finding below can be read alone. Findings marked &#8220;Analysis&#8221; are calculated for this article. The other findings come from the cited documents.<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>On December 20, 2024, the Federal Circuit held that a patent must claim at least the active ingredient to be listed for a drug. Patents that claim only device components do not qualify. [6]<\/li>\n\n\n\n<li>Between November 2023 and May 2025, the FTC challenged at least 600 listings in three rounds. Analysis: this total adds the FTC&#8217;s stated minimums of more than 100, more than 300 and more than 200. [8] [9] [10]<\/li>\n\n\n\n<li>In May 2025, the FTC said its first two rounds had led to delistings across 22 brand-name products. [10]<\/li>\n\n\n\n<li>Analysis: the two Teva-group letters of May 21, 2025 show 39 listing rows but only 22 unique patent numbers. Patent 10022510 appears under every product line in both letters. [2] [11]<\/li>\n\n\n\n<li>Analysis: Teva&#8217;s December 2025 request covers more than 200 listings. That is more than five times the 39 rows in the two May 2025 letters. [1] [2] [11]<\/li>\n\n\n\n<li>The FDA lists what brands submit and does not verify the claims. The court-ordered removals in this record came through counterclaims in patent litigation. [5] [12] [13] [6]<\/li>\n\n\n\n<li>Teva agreed to pay $35 million to settle a class action over QVAR patent listings. It also agreed to ask the FDA to delist QVAR patents. Teva denies wrongdoing. [14]<\/li>\n\n\n\n<li>Analysis: all 83 listing rows in the Novo Nordisk, Teva, Norton and Mylan letters carry the listing type &#8220;DP,&#8221; which stands for drug product. The FTC disputes whether the patents behind that label claim a drug product at all. [15] [2] [11] [3]<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Methodology: How We Counted FTC Letters, Listings and Patents<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What data we analyzed and for which period<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">We read FTC press releases, a policy statement and four warning letters dated from April 30, 2024 to May 21, 2025. We read the Federal Circuit opinions in Teva v. Amneal and Jazz v. Avadel and the First Circuit opinion in In re Lantus. We also read law-firm and news reports for events that the primary documents do not cover. The events run from 2002 to December 2025. A Congressional Research Service update from January 21, 2026 gave the latest status. [5]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We counted &#8220;listing rows&#8221; from the product tables in the Novo Nordisk, Teva, Norton (Waterford) and Mylan Specialty letters. One row is one patent number shown under one product line. We counted &#8220;unique patents&#8221; as the distinct patent numbers in a letter or in a group of letters. We took duplicates out before we counted. [15] [2] [11] [3]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We calculated elapsed days with a date calculator. We counted calendar days, including weekends.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What the analysis does not show<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The FTC gives its round totals as &#8220;more than&#8221; figures. Our sum of 600 is a floor, not an exact count.<\/li>\n\n\n\n<li>We did not read the letters to Novartis, Amphastar and Covis. We did not read the other letters of April 30, 2024.<\/li>\n\n\n\n<li>We did not test each patent&#8217;s claims ourselves. We relied on the courts and the FTC for the claim characterizations.<\/li>\n\n\n\n<li>The FTC and the FDA may count a &#8220;listing&#8221; in a different way than our row count.<\/li>\n\n\n\n<li>The Orange Book changes often. Each status in this article is true for the date of the cited source.<\/li>\n\n\n\n<li>The sources we reviewed report no Supreme Court ruling in Teva v. Amneal and no FTC round after May 21, 2025. They also do not report the result of the August 5, 2026 QVAR fairness hearing.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Definitions: Orange Book, Listing, Delisting Counterclaim and 30-Month Stay<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What is the Orange Book?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Orange Book is the FDA&#8217;s official source for the patent information that brand companies submit with an NDA. [4] Generic applicants must address each listed patent in their ANDA. [5]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What is a 30-month stay?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A 30-month stay is an automatic hold on FDA approval of a generic drug. It starts when a brand sues on a listed patent after a Paragraph IV challenge. It ends early if a court resolves the dispute sooner. [5]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What is a delisting counterclaim?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A delisting counterclaim is a claim that a generic applicant files in a patent suit. The statute lets the applicant seek an order that the brand &#8220;correct or delete the patent information&#8221; if the patent does not claim &#8220;the drug for which the application was approved.&#8221; [6] Avadel used the parallel provision in 21 U.S.C. 355(c)(3)(D)(ii)(I). [13]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What is an FDA patent listing dispute?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Anyone can tell the FDA that a listing is wrong. The FDA changes the listing only if the NDA holder agrees. [5] The FTC uses this process. After the FDA forwards a dispute, the brand has 30 days to withdraw or amend the listing. It can also certify under penalty of perjury that the listing complies with the requirements. [10]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What Can and Cannot Go in the Orange Book: A Reference Table<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The table below sorts patent types by listability. It combines the statute, the FDA rules and the court decisions in this article.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Patent type<\/th><th>Listable?<\/th><th>Basis<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>Drug substance (active ingredient)<\/td><td>Yes<\/td><td>Statute names it<\/td><td>[4] [7]<\/td><\/tr><tr><td>Drug product (formulation or composition)<\/td><td>Yes<\/td><td>Statute names it<\/td><td>[4] [7]<\/td><\/tr><tr><td>Method of using the approved drug<\/td><td>Yes, if the claims recite a method<\/td><td>Statute names it; Jazz applies it<\/td><td>[7] [13]<\/td><\/tr><tr><td>Process<\/td><td>No<\/td><td>FDA regulations say an NDA must not include it<\/td><td>[5]<\/td><\/tr><tr><td>Packaging<\/td><td>No<\/td><td>FDA regulations say an NDA must not include it<\/td><td>[5]<\/td><\/tr><tr><td>Metabolite<\/td><td>No<\/td><td>FDA regulations say an NDA must not include it<\/td><td>[5]<\/td><\/tr><tr><td>Intermediate<\/td><td>No<\/td><td>FDA regulations say an NDA must not include it<\/td><td>[5]<\/td><\/tr><tr><td>Device components only, no active ingredient claimed<\/td><td>No<\/td><td>Federal Circuit: the patent must claim at least the active ingredient<\/td><td>[6]<\/td><\/tr><tr><td>Injector mechanism that does not claim the drug<\/td><td>Not if it does not claim the drug<\/td><td>First Circuit: the complaint plausibly alleged improper listing of a patent that did not claim insulin glargine or the Lantus SoloSTAR<\/td><td>[16] [4]<\/td><\/tr><tr><td>REMS distribution system claimed as a system<\/td><td>Not as a method-of-use patent<\/td><td>Federal Circuit: system claims are not method claims; the wider REMS question is open<\/td><td>[13]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Patent Timeline: From Avanir (2014) to Teva&#8217;s 200-Listing Request (2025)<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Event<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>July 10, 2002<\/td><td>Fourth Circuit decides aaiPharma v. Thompson. The FDA&#8217;s role in Orange Book accuracy is &#8220;purely ministerial.&#8221;<\/td><td>[17]<\/td><\/tr><tr><td>August 20, 2014<\/td><td>Judge Stark (D. Del.) orders Avanir to remove a Nuedexta patent. A law-firm report says the order &#8220;appears to be the first&#8221; of its kind.<\/td><td>[12]<\/td><\/tr><tr><td>February 13, 2020<\/td><td>First Circuit decides In re Lantus. Improper listing of a device patent can support a Sherman Act claim.<\/td><td>[16]<\/td><\/tr><tr><td>January 5, 2021<\/td><td>Orange Book Transparency Act becomes law (Pub. L. 116-290).<\/td><td>[7]<\/td><\/tr><tr><td>February 24, 2023<\/td><td>Federal Circuit affirms delisting of a Xyrem REMS patent in Jazz v. Avadel.<\/td><td>[13]<\/td><\/tr><tr><td>September 14, 2023<\/td><td>FTC issues its policy statement. Improper listings may be an unfair method of competition.<\/td><td>[4] [18]<\/td><\/tr><tr><td>November 7, 2023<\/td><td>FTC challenges more than 100 patents (round 1).<\/td><td>[8]<\/td><\/tr><tr><td>April 30, 2024<\/td><td>FTC challenges more than 300 listings across 20 products (round 2).<\/td><td>[9]<\/td><\/tr><tr><td>June 10, 2024<\/td><td>Judge Chesler (D.N.J.) orders Teva to delist five ProAir HFA patents. The order is stayed pending appeal.<\/td><td>[18] [19]<\/td><\/tr><tr><td>December 20, 2024<\/td><td>Federal Circuit affirms in Teva v. Amneal (No. 24-1936).<\/td><td>[6]<\/td><\/tr><tr><td>January 22 and March 3, 2025<\/td><td>Federal Circuit stays the order for an en banc petition, then denies the petition.<\/td><td>[20]<\/td><\/tr><tr><td>May 21, 2025<\/td><td>FTC challenges more than 200 listings across 17 products (round 3).<\/td><td>[10]<\/td><\/tr><tr><td>May 22, 2025<\/td><td>Teva asks the Supreme Court to extend its deadline to August 1, 2025.<\/td><td>[21]<\/td><\/tr><tr><td>July 29, 2025<\/td><td>Teva&#8217;s infringement suit against Amneal is dismissed without prejudice.<\/td><td>[19]<\/td><\/tr><tr><td>December 10, 2025<\/td><td>Teva asks the FDA to remove more than 200 listings covering more than 30 products.<\/td><td>[1]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Elapsed-time analysis: how long enforcement took<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">These figures are our calculations from the dates above.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>818 days passed between the FTC policy statement (September 14, 2023) and Teva&#8217;s December 10, 2025 request.<\/li>\n\n\n\n<li>764 days passed between the first FTC letters (November 7, 2023) and the same request.<\/li>\n\n\n\n<li>193 days passed between the district court order (June 10, 2024) and the Federal Circuit decision (December 20, 2024).<\/li>\n\n\n\n<li>355 days passed between the Federal Circuit decision and Teva&#8217;s mass delisting request.<\/li>\n\n\n\n<li>About 9.8 years passed between the Avanir order (2014) and the Teva order (2024). The Avanir report hedges that it was a first, so treat this gap as an approximation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How the FDA&#8217;s Ministerial Role Created the Problem<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why does the FDA list patents it does not check?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA lists patent information that drug companies submit. It does not verify that information. It says it lacks patent-law expertise and calls its role &#8220;ministerial.&#8221; [5]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In aaiPharma v. Thompson (4th Cir. 2002), the court held that the FDA&#8217;s role is purely ministerial and that it can rely on the NDA holder&#8217;s self-report. [17] The Federal Circuit repeated the &#8220;purely ministerial&#8221; language in Jazz v. Avadel in 2023. [13]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What did the Orange Book Transparency Act change in 2021?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Act set a submission standard. It requires patents that claim the drug or a method of using it, and it bars other patent information. [7] It does not contain a general statement of FDA authority over patent listing. [7]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Act did add one removal route. When a patent is canceled or invalidated and the holder notifies the FDA, the Secretary must amend or remove the patent information. The Secretary may not remove it before a 180-day exclusivity period that relies on a Paragraph IV certification ends. [7]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why does the FDA dispute process stall?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Under the FDA&#8217;s process, the listing changes only if the NDA holder agrees. [5] A brand that believes its listing is proper can simply say so. A June 2024 law-firm alert reported that, according to the FDA database, none of the second-round manufacturers had removed patents. All had recertified their listings. [22]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">That gap explains the FTC&#8217;s choice of tools. It used a policy statement, warning letters and FDA dispute notices. [4] [10] It also filed an amicus brief in the Teva case. [18]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Teva v. Amneal: Litigation Breakdown<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What did the district court order on June 10, 2024?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Judge Stanley Chesler (D.N.J.) found that five Teva patents for ProAir HFA were improperly listed. He ordered Teva to remove them. The case is No. 2:23-cv-20964. The FTC filed an amicus brief for Amneal, and the court relied on it in part. [18] [19]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The court granted Amneal&#8217;s motion for judgment on the pleadings on the delisting counterclaim. [6] It stayed its order pending appeal, so the patents stayed listed. [18]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The facts around the product matter. Teva stopped producing ProAir HFA in 2022 and still kept nine patents listed. Amneal&#8217;s ANDA included a Paragraph IV certification for all nine. Teva sued on five. [20]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What did the Federal Circuit hold on December 20, 2024?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The panel was Judges Prost, Taranto and Hughes. Judge Prost wrote the opinion. The court affirmed the delisting order and lifted its stay. [6]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>The five patents and what they cover<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The patents are U.S. 8,132,712; 9,463,289; 9,808,587; 10,561,808; and 11,395,889. They relate to dose counters and canisters, which are device components. [6]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The court said that approving the inhaler as a drug &#8220;does not make the inhaler&#8217;s device parts a drug.&#8221; It also called Teva&#8217;s reading of the claims, &#8220;an active drug,&#8221; &#8220;far too broad to particularly point out and distinctly claim the drug approved in Teva&#8217;s NDA.&#8221; [6]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>A cross-check: nine listed, five litigated, four named by the FTC<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Haynes Boone reports that Teva kept nine patents listed for ProAir HFA and sued on five. [20] The FTC&#8217;s May 2025 letter names four ProAir HFA patents: 10022509, 10022510, 10086156 and 10695512. [2] None of the four is among the five court patents. [6]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Analysis: five plus four equals nine. The numbers fit, but we did not compare them with the Orange Book entry itself. If the fit holds, the FTC letter went after the ProAir HFA patents that the court order did not reach.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>What the court did not decide<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The court did not rule on Amneal&#8217;s separate argument that listed patents must be drug substance or drug product patents. [6] The appeal covered only the &#8220;delete&#8221; part of the counterclaim statute. Other counterclaims and Teva&#8217;s infringement claims were still pending in the district court. [6]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What happened after the ruling: en banc, the Supreme Court and the dismissal<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Federal Circuit stayed the delisting order on January 22, 2025, after Teva asked for en banc review. It denied that request on March 3, 2025. [20] Unless the Supreme Court acted, Teva had to send its delisting requests to the FDA by March 17. [20]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On May 22, 2025, Teva asked for more time to petition the Supreme Court. The petition was due June 2, 2025, and Teva asked for August 1, 2025. [21] Teva said it would argue that the Federal Circuit misread &#8220;claim[] the drug&#8221; and conflicted with Supreme Court decisions. [21]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On July 29, 2025, the district court dismissed Teva&#8217;s infringement suit against Amneal without prejudice. The dismissal came days before the extended petition date. [19] The sources we reviewed report no Supreme Court ruling on the question.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Four Court Decisions Compared: Avanir, Lantus, Xyrem and ProAir<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Four court decisions apply the same claim-based idea to different kinds of patents. The table sets them side by side.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Case<\/th><th>Court and date<\/th><th>Product<\/th><th>What the patent claimed<\/th><th>Result<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>Avanir v. Actavis<\/td><td>D. Del., Aug. 20, 2014<\/td><td>Nuedexta<\/td><td>Not stated in the report we read<\/td><td>Court found it did not claim &#8220;the drug for which the application was approved&#8221; and ordered removal<\/td><td>[12]<\/td><\/tr><tr><td>In re Lantus<\/td><td>1st Cir., Feb. 13, 2020<\/td><td>Lantus SoloSTAR (insulin glargine)<\/td><td>U.S. 8,556,864: drive mechanisms of an injector pen. It does not claim insulin glargine.<\/td><td>Reversed dismissal. Improper listing can support a Sherman Act claim.<\/td><td>[16]<\/td><\/tr><tr><td>Jazz v. Avadel<\/td><td>Fed. Cir., Feb. 24, 2023<\/td><td>Xyrem<\/td><td>U.S. 8,731,963: a single-pharmacy distribution system tied to the REMS<\/td><td>Affirmed delisting. System claims are not method claims.<\/td><td>[13]<\/td><\/tr><tr><td>Teva v. Amneal<\/td><td>Fed. Cir., Dec. 20, 2024<\/td><td>ProAir HFA<\/td><td>Five patents on dose counters and canisters<\/td><td>Affirmed delisting. A listed patent must claim at least the active ingredient.<\/td><td>[6]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>In re Lantus (1st Cir. 2020): when a bad listing becomes an antitrust claim<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Sanofi submitted the &#8216;864 patent for listing in 2013. The patent claims drive mechanisms for the SoloSTAR pen. It does not claim insulin glargine. [16] Judge Kayatta wrote that &#8220;only patents that claim the drug for which the NDA is submitted should be listed in the Orange Book.&#8221; [16]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The court gave brands a defense. A brand can show that it made a reasonable, good-faith attempt to comply with the Hatch-Waxman scheme. The court said Sanofi must prove that defense on remand. [16] The FTC cites Lantus in its policy statement. [4]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Jazz v. Avadel (Fed. Cir. 2023): when a system claim is not a method claim<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Jazz listed a patent on a distribution system for Xyrem. The court held that claims to &#8220;a system comprising computer memories and a data processor are not claims to a method.&#8221; [13] The patent therefore could not be a method-of-use patent, and the delisting order stood. [13]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>What Jazz did not decide about REMS patents<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The court did not decide Avadel&#8217;s broader argument about whether REMS patents can ever be listed. [13] That question stays open. A brand with a REMS-related listing cannot treat Jazz as a safe harbor. A generic applicant cannot treat it as a blanket win.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Avanir v. Actavis (D. Del. 2014): the early counterclaim order<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Judge Stark ordered Avanir to remove a patent for Nuedexta from the Orange Book. He had first told Avanir to &#8220;try again&#8221; after an earlier attempt to remove it failed. [12] A law-firm report said the order &#8220;appears to be the first&#8221; requiring a brand company to delist a patent. [12]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How the four decisions fit together<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The defects differ. Lantus and ProAir involve device parts. Xyrem involves a system claim in a method-of-use slot. The test is the same. The court reads the claims and asks what the patent claims. Patent titles, product marketing and the existence of a combination product do not change the answer. [16] [13] [6]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The FTC Campaign by the Numbers: Three Rounds, One Test<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Step<\/th><th>Date<\/th><th>Listings challenged<\/th><th>Products<\/th><th>Reported outcome<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>Policy statement<\/td><td>Sept. 14, 2023<\/td><td>Not applicable<\/td><td>Not applicable<\/td><td>Improper listings may violate Section 5 of the FTC Act<\/td><td>[4]<\/td><\/tr><tr><td>Round 1<\/td><td>Nov. 7, 2023<\/td><td>More than 100 patents<\/td><td>Asthma inhalers, epinephrine autoinjectors and others<\/td><td>GSK, Impax (Amneal) and Kaleo delisted some patents<\/td><td>[8] [23]<\/td><\/tr><tr><td>Round 2<\/td><td>Apr. 30, 2024<\/td><td>More than 300<\/td><td>20<\/td><td>With round 1, led to delistings across 22 products (FTC, May 2025)<\/td><td>[9] [10]<\/td><\/tr><tr><td>Round 3<\/td><td>May 21, 2025<\/td><td>More than 200<\/td><td>17<\/td><td>Companies &#8220;have since withdrawn most of the disputed listings&#8221; (FTC, Dec. 2025)<\/td><td>[10] [1]<\/td><\/tr><tr><td>Teva request<\/td><td>Dec. 10, 2025<\/td><td>More than 200<\/td><td>More than 30<\/td><td>Teva asks the FDA to remove the listings<\/td><td>[1]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Round 1 (November 2023): more than 100 patents<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The FTC challenged more than 100 patents for products that included asthma inhalers and epinephrine autoinjectors. [8] Some drugmakers delisted the patents. Others said their patents were properly listed. [5]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Fierce Pharma reported that GSK withdrew four of five flagged patents and removed others that the FTC had not challenged. It also reported that Boehringer, AstraZeneca and GSK committed to cap monthly out-of-pocket inhaler costs at $35. [23]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Round 2 (April 2024): more than 300 listings across 20 products<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">DLA Piper reported that the FTC sent letters to 10 companies disputing more than 300 patents on 20 brand-name products. The products included weight-loss and diabetes injectables, asthma and COPD inhalers, and a diabetes nasal spray. [9]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FTC stated its view of the law. It said that drug-device patents claiming devices or device components &#8220;untethered&#8221; from any drug or formulation are not listable. [9] FTC Chair Lina Khan said that by challenging junk patent filings, &#8220;the FTC is fighting these illegal tactics.&#8221; [9]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Novo Nordisk letter shows the format. It names Ozempic, Saxenda and Victoza and gives patent numbers for each. It cites Section 5 of the FTC Act, the FDA dispute process and the September 2023 policy statement. It sets no response deadline. [15] Fierce Pharma reported that Novo Nordisk said it was reviewing the letter. [23]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Boehringer Ingelheim took the opposite position. It said it had &#8220;never wrongfully submitted patents for listing in the Orange Book&#8221; and believed its patents were &#8220;valid, enforceable and properly listed.&#8221; [23]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Round 3 (May 2025): more than 200 listings across 17 products<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The FTC sent letters to Novartis, Amphastar, Mylan Specialty, Covis and three Teva entities. It cited the Federal Circuit ruling. [10] The FTC also gave a clock. After the FDA forwards a dispute, the brand has 30 days to withdraw or amend the listing or to certify under penalty of perjury that it complies. [10]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Teva letter quotes the court for the rule that a patent qualifies when it &#8220;particularly points out and distinctly claims the drug as the invention.&#8221; It says that Teva had requested delisting of the patents at issue in Teva v. Amneal &#8220;but many others remain listed.&#8221; [2]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Mylan letter supports the title of this article. It disputes four patents for EpiPen and EpiPen Jr. It adds: &#8220;Although we have not, at this time, disputed the listing of any other Mylan patents.&#8221; [3] The FTC drew a line patent by patent. It did not attack the rest of the portfolio.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>December 2025: Teva&#8217;s request for more than 200 removals<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The FTC said Teva asked the FDA to remove more than 200 improper listings covering more than 30 products. [1] Earlier, Teva had told Fierce Pharma that it believed its patents were properly listed. Fierce also reported that Teva&#8217;s annual report said the FTC investigation could have a &#8220;material adverse effect&#8221; on its business. [24]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Listing rows versus unique patents in four FTC letters<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Table 1 is our analysis. It counts rows and distinct patent numbers in the letter tables.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Letter<\/th><th>Products in the table<\/th><th>Listing rows<\/th><th>Unique patent numbers<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>Novo Nordisk, Apr. 30, 2024<\/td><td>Ozempic, Saxenda, Victoza<\/td><td>36<\/td><td>18<\/td><td>[15]<\/td><\/tr><tr><td>Teva Branded, May 21, 2025<\/td><td>ProAir HFA, ProAir DigiHaler, ProAir RespiClick, QVAR 40\/80<\/td><td>33<\/td><td>20<\/td><td>[2]<\/td><\/tr><tr><td>Norton (Waterford), May 21, 2025<\/td><td>QVAR RediHaler<\/td><td>6<\/td><td>6<\/td><td>[11]<\/td><\/tr><tr><td>Mylan Specialty, May 21, 2025<\/td><td>EpiPen, EpiPen Jr<\/td><td>8<\/td><td>4<\/td><td>[3]<\/td><\/tr><tr><td>Teva and Norton letters combined<\/td><td>Five product lines in the Teva letter plus one in the Norton letter<\/td><td>39<\/td><td>22<\/td><td>Analysis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Novo table shows the same 17 patent numbers under Ozempic and under Saxenda, and two numbers under Victoza. One Victoza number repeats. That gives 36 rows from 18 patents. [15]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Teva-group letters show the same pattern. Four patents (10022509, 10022510, 10086156 and 10695512) appear under ProAir HFA, QVAR 40\/80 and QVAR RediHaler. [2] [11] Patent 10022510 also appears under ProAir DigiHaler and ProAir RespiClick. [2] It therefore sits under five product lines and four NDA numbers in the letter tables. [2] [11]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">One patent that fails the claim test can create many failing listings. A reviewer must test the patent once and then check every NDA where it appears.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scale also matters. The two Teva-group letters hold 39 rows. Teva&#8217;s December 2025 request covers more than 200 listings. [1] The request therefore reaches well beyond the patents the two letters name. Fierce Pharma also reported about 60 Teva patents across five brands in round 2. [23] We cannot say which listings make up the rest.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>What the &#8220;DP&#8221; code shows<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Every row in the four letter tables carries the listing type &#8220;DP.&#8221; We count 83 such rows: 36 in the Novo Nordisk letter, 33 in the Teva letter, 6 in the Norton letter and 8 in the Mylan letter. [15] [2] [11] [3] The brand picks the code when it submits a listing. The FDA does not check it. [5]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The code is a label. The claims decide the category. The Lantus court looked at what the patent claimed. The patent did not claim insulin glargine, so the court held that the complaint plausibly alleged an improper listing. [16]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Who Complied, Who Refused, and What Refusal Cost<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Products named<\/th><th>Documented response<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>GSK and Glaxo Group<\/td><td>Anoro, Trelegy, Arnuity and Ventolin HFA; Advair HFA, Flovent HFA, Incruse and Breo<\/td><td>Delisted some patents, but kept several of the targeted ones<\/td><td>[18]<\/td><\/tr><tr><td>Kaleo<\/td><td>AUVI-Q, naloxone<\/td><td>Delisted some patents<\/td><td>[18]<\/td><\/tr><tr><td>Boehringer Ingelheim<\/td><td>Respimat inhalers<\/td><td>Said its patents were &#8220;valid, enforceable and properly listed&#8221;<\/td><td>[23]<\/td><\/tr><tr><td>Novo Nordisk<\/td><td>Ozempic, Saxenda, Victoza<\/td><td>Said it was reviewing the letter<\/td><td>[23]<\/td><\/tr><tr><td>Teva<\/td><td>ProAir, QVAR and others<\/td><td>Delisting of five ProAir HFA patents ordered in June 2024 and affirmed in December 2024; a $35 million QVAR class settlement; a December 2025 request to remove more than 200 listings<\/td><td>[6] [14] [1]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What did refusal cost Teva?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Teva faced a court order and a class action. It later made a mass delisting request. In the QVAR class action, the settlement fund is $35 million. The class period runs from January 1, 2015 to July 31, 2025. [14]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The plaintiffs allege that Teva listed QVAR patents that did not meet the listing requirements. Teva denies the allegation. Teva also agreed to ask the FDA to delist QVAR patents. The fairness hearing was set for August 5, 2026. [14] This article does not report the hearing outcome.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why do some brands delist at once and others fight?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The record does not give company reasons, so this section is analysis. Before December 20, 2024, a brand could argue about the meaning of &#8220;claims the drug.&#8221; After that date, a device-only claim set faced a precedential reading that requires the active ingredient. [6] [21]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Brands with mixed portfolios still have room to argue. The Federal Circuit left the drug substance and drug product question open. [6] The REMS question is also open. [13]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What does a good-faith defense look like?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Lantus offers the clearest guide. The First Circuit said a brand can defend an improper listing by proving a reasonable, good-faith attempt to comply with the statute. [16] In our reading, a record that shows a claim-by-claim review before each submission supports that defense.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Four Channels That Can Remove an Improper Orange Book Listing<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This taxonomy is original to this article. It is not an established industry classification. It sorts the removal routes by who starts them and what each can order.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Channel<\/th><th>Who starts it<\/th><th>What it can achieve<\/th><th>Documented example<\/th><th>Limit<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>1. FDA dispute process<\/td><td>Anyone, including the FTC<\/td><td>Listing change<\/td><td>FTC dispute notices to the FDA, 2025<\/td><td>The FDA changes the listing only if the NDA holder agrees<\/td><td>[5] [10]<\/td><\/tr><tr><td>2. FTC policy and letters<\/td><td>FTC Bureau of Competition<\/td><td>Pressure to withdraw or certify under penalty of perjury<\/td><td>Three letter rounds, 2023 to 2025<\/td><td>Letters ask for action but do not order it. The sources we read show no FTC complaint over a listing.<\/td><td>[4] [10] [15]<\/td><\/tr><tr><td>3. Delisting counterclaim<\/td><td>Generic or follow-on applicant sued for infringement<\/td><td>Court order to correct or delete the listing<\/td><td>Avanir (2014), Jazz (2023), Teva (2024)<\/td><td>Needs a pending patent suit and a patent that fails the claim test<\/td><td>[12] [13] [6]<\/td><\/tr><tr><td>4. Private antitrust suit<\/td><td>Purchasers and payors<\/td><td>Damages and negotiated delisting<\/td><td>Lantus (2020), QVAR class action<\/td><td>Brand can defend with good-faith compliance; years of delay<\/td><td>[16] [14]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Channel 3 produced the sharpest legal rule. Channel 2 produced the largest volume of removals. Channel 4 added a cash cost. Channel 1 did the least alone. It depends on the brand&#8217;s consent. [5]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What Happens to Generic Pricing When a Listing Falls?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">An improper listing delays generic entry. Generic entry cuts prices. The FDA measured how much.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">FDA analysts found that median generic prices were 39% below the brand price with one generic competitor, 54% below with two, 79% below with four, and more than 95% below with six or more. The measure was manufacturer price (AMP) for products with first generic entry from January 2015 to December 2017. [25]<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Illustrative arithmetic: price per $100 of brand price<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Table 2 turns the FDA percentages into prices. It is our calculation. It is not a forecast for any drug.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Generic competitors<\/th><th>FDA median reduction<\/th><th>Implied price per $100 of brand price<\/th><\/tr><\/thead><tbody><tr><td>1<\/td><td>39%<\/td><td>$61<\/td><\/tr><tr><td>2<\/td><td>54%<\/td><td>$46<\/td><\/tr><tr><td>4<\/td><td>79%<\/td><td>$21<\/td><\/tr><tr><td>6 or more<\/td><td>More than 95%<\/td><td>Under $5<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA sample counts authorized generics as generic products. It covers only first entries in 2015 to 2017. [25] The numbers show the direction and rough size of the effect. They do not predict a specific launch.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why timing matters more than count<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A stay lasts up to 30 months. [5] A brand that lists a failing patent and sues can hold the stay in place while the listing question is open. The Teva record shows how long this can take. The district court ordered delisting on June 10, 2024. [18] Teva made its mass delisting request on December 10, 2025. [1] That is 548 days (our calculation).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What This Means for Brands, Generic Filers, Intelligence Teams and Legal Teams<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What this means for brand manufacturers<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Review each listing against its claims. Start with device, packaging, software and distribution-system patents.<\/li>\n\n\n\n<li>Check each NDA that carries the same patent. Table 1 shows one patent under five product lines.<\/li>\n\n\n\n<li>Keep a written record of the review. The Lantus defense turns on a reasonable, good-faith attempt to comply. [16]<\/li>\n\n\n\n<li>Plan for the 30-day response window and the penalty-of-perjury certification. [10]<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What this means for generic and follow-on filers<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Read the independent claims of every listed patent before you plan a certification strategy.<\/li>\n\n\n\n<li>Use a delisting counterclaim when a patent fails the claim test and the brand sues on it. [6]<\/li>\n\n\n\n<li>Do not assume a removal will come fast. In Teva v. Amneal, the Federal Circuit stayed its own order for an en banc petition. [20]<\/li>\n\n\n\n<li>Remember that the 2024 order concerned a product Teva no longer made. [20] The facts of your product may differ.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What this means for competitive intelligence and business development teams<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A listed expiration date is not an entry date. A listing that fails the claim test stays in the Orange Book until someone removes it. In the Teva case, the patents stayed listed while the appeal ran. [18] Screen each listing before you build a loss-of-exclusivity model.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Track changes, not only snapshots. DrugPatentWatch publishes guidance on <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/delistings-patent-corrections-and-supplements-monitor-changes-and-predict-the-patent-cliff-in-the-fda-orange-book\/\">delistings, patent corrections and supplements<\/a> in the Orange Book. Use such a feed to find candidates. Then read the claims yourself.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What this means for legal and compliance teams<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The cost of an improper listing is not only a lost counterclaim. It can include a class action and a delisting commitment. [14] It can also include an FTC letter that your company must answer under penalty of perjury. [10] Assign an owner for each listing decision.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>A Five-Question Screen for Any Orange Book Patent<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This screen is our framework. It applies the statute and the cases above. It is not legal advice.<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>What do the independent claims recite? Read the claims. Do not rely on the title or abstract.<\/li>\n\n\n\n<li>Does any independent claim recite the active ingredient named in the NDA? If not, a product-type patent fails under Teva v. Amneal. [6]<\/li>\n\n\n\n<li>If the patent is a method-of-use patent, does it claim a method of using the approved drug? System or apparatus claims are not method claims. [13]<\/li>\n\n\n\n<li>Could a claim of patent infringement reasonably be asserted against the NDA product? The statute asks this question. [7]<\/li>\n\n\n\n<li>Is the same patent listed under more than one NDA? Run the first four questions again for each listing. Table 1 shows why.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">A patent that fails question 2 or 3 is a delisting candidate. A patent that passes all five questions still faces the normal validity and infringement questions. The screen tests listability only.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Four Misreadings of the FTC&#8217;s Position<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Misreading 1: &#8220;The FTC wants brands to hold fewer patents&#8221;<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The record shows a narrower aim. The Mylan letter disputes four patents and says the FTC has not disputed any other Mylan patents. [3] The FTC&#8217;s stated test looks at what a patent claims. [4]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Misreading 2: &#8220;A listed patent has passed a check&#8221;<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No FDA check exists. The FDA lists what the brand submits and does not verify it. [5] A listing shows that the brand submitted a patent. It does not show that the patent meets the listing rule.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Misreading 3: &#8220;Delisting decides validity or infringement&#8221;<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Delisting changes the Orange Book entry. In Teva v. Amneal, the Federal Circuit decided the delisting counterclaim. Teva&#8217;s infringement claims were still pending in the district court when it ruled. [6]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Misreading 4: &#8220;Only device patents are at risk&#8221;<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The FTC&#8217;s stated position in round 2 concerned device patents. [9] Jazz v. Avadel shows that a distribution-system claim can also fail the listing test. [13]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What Happens Next: Open Questions and Scenarios<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What questions remain open?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Congressional Research Service names three issues for Congress. They are who should monitor Orange Book listings, whether the law should say more about patent types such as REMS and device patents, and whether the 30-month stay should apply to only some patent types, such as active-ingredient patents. [5]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Forecast: what the open questions could change<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">This paragraph is a forecast, not a confirmed event. The statute and the Teva v. Amneal reading cover device-only patents well. Formulation, REMS and combination-product edge cases have less case law. [6] [13] The next dispute will probably test one of those edges.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Scenario analysis: five documented paths for a brand with a failing listing<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The paths below come from documented outcomes. They are not predictions.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Path<\/th><th>Documented example<\/th><th>Documented consequence<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>Delist after the first letter<\/td><td>GSK and Kaleo in round 1<\/td><td>Some patents removed; several targeted patents stayed listed<\/td><td>[18] [23]<\/td><\/tr><tr><td>Defend the listings<\/td><td>Boehringer Ingelheim statement<\/td><td>The sources we read report no court ruling on these listings<\/td><td>[23]<\/td><\/tr><tr><td>Litigate to a final order<\/td><td>Teva and ProAir HFA<\/td><td>District order in June 2024; Federal Circuit affirmance in December 2024<\/td><td>[18] [6]<\/td><\/tr><tr><td>Carry the exposure into a class action<\/td><td>Teva and QVAR<\/td><td>$35 million fund and a delisting commitment<\/td><td>[14]<\/td><\/tr><tr><td>Delist in bulk after an FTC probe<\/td><td>Teva, December 2025<\/td><td>Request to remove more than 200 listings on more than 30 products<\/td><td>[1]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>What to watch<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The status of the QVAR settlement after the August 5, 2026 fairness hearing. [14]<\/li>\n\n\n\n<li>Any FTC round after May 21, 2025. The sources we reviewed report none.<\/li>\n\n\n\n<li>New delisting counterclaims that cite Teva v. Amneal.<\/li>\n\n\n\n<li>Congressional action on the three issues in the CRS report. [5]<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Takeaways<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The FTC tests each Orange Book patent against its claims. The count of listings is not the test. [4] [3]<\/li>\n\n\n\n<li>A product patent must claim at least the active ingredient. Device-component patents fail. [6]<\/li>\n\n\n\n<li>A system claim is not a method-of-use claim. [13]<\/li>\n\n\n\n<li>The FTC challenged at least 600 listings in three rounds from November 2023 to May 2025. This is a floor calculated from the FTC&#8217;s &#8220;more than&#8221; figures. [8] [9] [10]<\/li>\n\n\n\n<li>The two Teva-group letters of May 2025 show 39 rows but 22 unique patents. One patent appears under five product lines. [2] [11]<\/li>\n\n\n\n<li>Teva asked the FDA on December 10, 2025 to remove more than 200 listings on more than 30 products. [1]<\/li>\n\n\n\n<li>The FDA does not verify listings. Court counterclaims produced the binding removal orders in this record. [5] [6]<\/li>\n\n\n\n<li>All 83 listing rows in four FTC letters carry the &#8220;DP&#8221; label. The label does not decide the category. The claims do. [15] [2] [11] [3] [16]<\/li>\n\n\n\n<li>Improper listings can also lead to private antitrust cost. Teva agreed to a $35 million QVAR class settlement and denies wrongdoing. [14]<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>FAQ<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Can the FDA remove a patent from the Orange Book on its own?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Not in the normal case. The FDA calls its role ministerial and changes a disputed listing only if the NDA holder agrees. [5] The Orange Book Transparency Act adds one route: after a patent is canceled or invalidated and the holder notifies the FDA, the FDA must amend or remove the patent information. [7]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Can the FTC delist a patent directly?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The documents we reviewed show no direct FTC delisting power. The FTC sends dispute notices to the FDA and warning letters to the brand. It relies on a Section 5 theory in its policy statement. [4] [10]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Is having many patents on one drug illegal?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The FTC record we reviewed does not describe patent count as the issue. Its Mylan letter disputes four EpiPen patents and says the FTC has not disputed any other Mylan patents. [3] The issue is whether each listed patent meets the listing rule.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What are the consequences of an improper listing?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The sources we reviewed describe no fixed statutory fine. They describe other consequences: a court order to delist, an antitrust claim under Lantus, and a class settlement in QVAR. [6] [16] [14] A brand that certifies a listing to the FDA after an FTC dispute does so under penalty of perjury. [10]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Can a method-of-use patent be listed?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yes, if it claims a method of using the drug for an approved use. [7] The claims must recite a method. In Jazz v. Avadel, the court held that system claims did not qualify. [13]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Do formulation patents qualify for the Orange Book?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yes. The FTC policy statement lists drug product patents, meaning formulation or composition patents, as listable. [4] The Federal Circuit did not decide Amneal&#8217;s drug substance versus drug product argument. [6]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What happened to the ProAir HFA patents after the ruling?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Federal Circuit affirmed delisting of five patents. [6] The FTC&#8217;s May 2025 letter says Teva had requested delisting of those patents. [2] The district court later dismissed Teva&#8217;s infringement suit without prejudice. [19]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Does the Teva v. Amneal ruling apply to biologic patent lists?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The ruling reads 21 U.S.C. 355(b)(1)(A)(viii), the small-molecule NDA listing statute. [6] The sources we reviewed do not apply it to patent lists for biologics.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What must a brand do within 30 days of an FTC dispute?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">After the FDA forwards the dispute, the brand must withdraw or amend the listing. It can also certify under penalty of perjury that the listing complies with the requirements. [10]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How long does a delisting fight take?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Teva dispute gives one data point. The Federal Circuit decided the appeal 193 days after the district order. Teva&#8217;s mass delisting request came 548 days after that order. Both figures are our calculations from the dates in the record. [18] [6] [1]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>References<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Federal Trade Commission. (2025, December 10). <em>Teva removes over 200 improper patent listings under pressure from FTC<\/em> [Press release]. <a href=\"https:\/\/www.ftc.gov\/node\/326986\">https:\/\/www.ftc.gov\/node\/326986<\/a><\/li>\n\n\n\n<li>Moen, K. (2025, May 21). <em>[Letter to B. Savage, Teva Pharmaceuticals, on improper Orange Book patent listings for ProAir HFA, ProAir DigiHaler, ProAir RespiClick, QVAR 40 and QVAR 80]<\/em>. Federal Trade Commission, Bureau of Competition. <a href=\"https:\/\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/2025-05-21-teva-branded-pharm-orange-book-warning-letter.pdf\">https:\/\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/2025-05-21-teva-branded-pharm-orange-book-warning-letter.pdf<\/a><\/li>\n\n\n\n<li>Moen, K. (2025, May 21). <em>[Letter to Mylan Specialty LP and Viatris Inc. on improper Orange Book patent listings for EpiPen and EpiPen Jr.]<\/em>. Federal Trade Commission, Bureau of Competition. <a href=\"https:\/\/search.ftc.gov\/system\/files\/ftc_gov\/pdf\/2025-05-21-mylan-specialty-orange-book-warning-letter.pdf\">https:\/\/search.ftc.gov\/system\/files\/ftc_gov\/pdf\/2025-05-21-mylan-specialty-orange-book-warning-letter.pdf<\/a><\/li>\n\n\n\n<li>Federal Trade Commission. (2023, September 14). <em>Policy statement of the Federal Trade Commission concerning brand drug manufacturers&#8217; improper listing of patents in the Orange Book<\/em>. <a href=\"https:\/\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/p239900orangebookpolicystatement092023.pdf\">https:\/\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/p239900orangebookpolicystatement092023.pdf<\/a><\/li>\n\n\n\n<li>Congressional Research Service. (2026, January 21). <em>Patent listing in FDA&#8217;s Orange Book<\/em> (CRS In Focus IF12644). <a href=\"https:\/\/www.everycrsreport.com\/files\/2026-01-21_IF12644_854d9749fa2c36c99902210cbbaa4e3e51c7f03d.html\">https:\/\/www.everycrsreport.com\/files\/2026-01-21_IF12644_854d9749fa2c36c99902210cbbaa4e3e51c7f03d.html<\/a><\/li>\n\n\n\n<li><em>Teva Branded Pharmaceutical Products R&amp;D, Inc. v. Amneal Pharmaceuticals of New York, LLC<\/em>, No. 2024-1936, 124 F.4th 898 (Fed. Cir. 2024, December 20). <a href=\"https:\/\/www.cafc.uscourts.gov\/opinions-orders\/24-1936.OPINION.12-20-2024_2439730.pdf\">https:\/\/www.cafc.uscourts.gov\/opinions-orders\/24-1936.OPINION.12-20-2024_2439730.pdf<\/a><\/li>\n\n\n\n<li>Orange Book Transparency Act of 2020, Pub. L. No. 116-290 (2021, January 5). <a href=\"https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-116publ290\/html\/PLAW-116publ290.htm\">https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-116publ290\/html\/PLAW-116publ290.htm<\/a><\/li>\n\n\n\n<li>Federal Trade Commission. (2023, November 7). <em>FTC challenges more than 100 patents as improperly listed in the FDA&#8217;s Orange Book<\/em> [Press release]. <a href=\"https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2023\/11\/ftc-challenges-more-100-patents-improperly-listed-fdas-orange-book\">https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2023\/11\/ftc-challenges-more-100-patents-improperly-listed-fdas-orange-book<\/a><\/li>\n\n\n\n<li>DLA Piper. (2024, May 3). <em>FTC continues to scrutinize Orange Book patent listings<\/em>. <a href=\"https:\/\/www.dlapiper.com\/insights\/publications\/2024\/05\/ftc-continues-to-scrutinize-orange-book-patent-listings\">https:\/\/www.dlapiper.com\/insights\/publications\/2024\/05\/ftc-continues-to-scrutinize-orange-book-patent-listings<\/a><\/li>\n\n\n\n<li>Federal Trade Commission. (2025, May 21). <em>FTC renews challenge of more than 200 improper patent listings<\/em> [Press release]. <a href=\"https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2025\/05\/ftc-renews-challenge-more-200-improper-patent-listings\">https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2025\/05\/ftc-renews-challenge-more-200-improper-patent-listings<\/a><\/li>\n\n\n\n<li>Moen, K. (2025, May 21). <em>[Letter to Norton (Waterford) Limited on QVAR RediHaler]<\/em>. Federal Trade Commission, Bureau of Competition. <a href=\"https:\/\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/2025-05-21-norton-waterford-orange-book-warning-letter.pdf\">https:\/\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/2025-05-21-norton-waterford-orange-book-warning-letter.pdf<\/a><\/li>\n\n\n\n<li>Arent Fox Schiff LLP. (2014, September 19). <em>Order granting delisting counterclaim: A first?<\/em> (reporting <em>Avanir Pharmaceuticals, Inc. v. Actavis South Atlantic LLC<\/em>, No. 11-0704, ECF No. 518 (D. Del. 2014, August 20)). <a href=\"https:\/\/www.afslaw.com\/perspectives\/alerts\/order-granting-delisting-counterclaim-first\">https:\/\/www.afslaw.com\/perspectives\/alerts\/order-granting-delisting-counterclaim-first<\/a><\/li>\n\n\n\n<li><em>Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC<\/em>, No. 2023-1186 (Fed. Cir. 2023, February 24). <a href=\"https:\/\/www.cafc.uscourts.gov\/opinions-orders\/23-1186.OPINION.2-24-2023_2085825.pdf\">https:\/\/www.cafc.uscourts.gov\/opinions-orders\/23-1186.OPINION.2-24-2023_2085825.pdf<\/a><\/li>\n\n\n\n<li>QVAR Antitrust Settlement. (n.d.). <em>Iron Workers District Council of New England Health and Welfare Fund v. Teva Pharmaceuticals<\/em>, No. 23-cv-11131-NMG (D. Mass.) [Settlement website]. <a href=\"https:\/\/qvarantitrustsettlement.com\/\">https:\/\/qvarantitrustsettlement.com\/<\/a><\/li>\n\n\n\n<li>Rao, R. (2024, April 30). <em>[Letter to S. Benz and R. Fischer, Novo Nordisk Inc., on Ozempic, Saxenda and Victoza]<\/em>. Federal Trade Commission, Bureau of Competition. <a href=\"https:\/\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/novo-nordisk-ozempic-saxenda-victoza-_4302024.pdf\">https:\/\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/novo-nordisk-ozempic-saxenda-victoza-_4302024.pdf<\/a><\/li>\n\n\n\n<li><em>In re Lantus Direct Purchaser Antitrust Litigation<\/em>, 950 F.3d 1 (1st Cir. 2020, February 13). <a href=\"https:\/\/www.ca1.uscourts.gov\/sites\/ca1\/files\/opnfiles\/18-2086P-01A.pdf\">https:\/\/www.ca1.uscourts.gov\/sites\/ca1\/files\/opnfiles\/18-2086P-01A.pdf<\/a><\/li>\n\n\n\n<li><em>aaiPharma Inc. v. Thompson<\/em>, 296 F.3d 227 (4th Cir. 2002, July 10). Case summary: <a href=\"https:\/\/www.casebriefs.com\/blog\/law\/patent-law\/patent-law-keyed-to-adelman\/the-hatch-waxman-act\/aaipharma-inc-v-thompson\/\">https:\/\/www.casebriefs.com\/blog\/law\/patent-law\/patent-law-keyed-to-adelman\/the-hatch-waxman-act\/aaipharma-inc-v-thompson\/<\/a><\/li>\n\n\n\n<li>White &amp; Case LLP. (2024, August 20). <em>The current status of FTC&#8217;s Orange Book listings challenge: A mixed bag<\/em>. <a href=\"https:\/\/www.whitecase.com\/insight-our-thinking\/current-status-ftcs-orange-book-listings-challenge-mixed-bag\">https:\/\/www.whitecase.com\/insight-our-thinking\/current-status-ftcs-orange-book-listings-challenge-mixed-bag<\/a><\/li>\n\n\n\n<li>Bloomberg Law. (2025, July 30). <em>Teva drops inhaler patent infringement lawsuit against Amneal<\/em>. <a href=\"https:\/\/news.bloomberglaw.com\/ip-law\/teva-drops-inhaler-patent-infringement-lawsuit-against-amneal\">https:\/\/news.bloomberglaw.com\/ip-law\/teva-drops-inhaler-patent-infringement-lawsuit-against-amneal<\/a><\/li>\n\n\n\n<li>Pelletier, B., &amp; Blake, A. (2025, March 13). <em>Teva v. Amneal: Reshaping generic drug rights<\/em>. Haynes Boone. <a href=\"https:\/\/www.haynesboone.com\/news\/publications\/teva-v-amneal-reshaping-generic-drug-rights\">https:\/\/www.haynesboone.com\/news\/publications\/teva-v-amneal-reshaping-generic-drug-rights<\/a><\/li>\n\n\n\n<li>Teva Branded Pharmaceutical Products R&amp;D LLC, Norton (Waterford) Ltd., &amp; Teva Pharmaceuticals USA, Inc. (2025, May 22). <em>Application for an extension of time to file a petition for a writ of certiorari<\/em> (No. 24A1149). Supreme Court of the United States. <a href=\"https:\/\/www.supremecourt.gov\/DocketPDF\/24\/24A1149\/359510\/20250522170811156_ProAir%20-%20SCt%20Extension%20Request_EFILE.pdf\">https:\/\/www.supremecourt.gov\/DocketPDF\/24\/24A1149\/359510\/20250522170811156_ProAir%20-%20SCt%20Extension%20Request_EFILE.pdf<\/a><\/li>\n\n\n\n<li>Crowell &amp; Moring LLP. (2024, June 27). <em>The FTC strikes out: Drug manufacturers refuse to play ball and delist Orange Book patents in response to FTC warning letters<\/em>. <a href=\"https:\/\/crowell.com\/en\/insights\/client-alerts\/the-ftc-strikes-out-drug-manufacturers-refuse-to-play-ball-and-delist-orange-book-patents-in-response-to-ftc-warning-letters\">https:\/\/crowell.com\/en\/insights\/client-alerts\/the-ftc-strikes-out-drug-manufacturers-refuse-to-play-ball-and-delist-orange-book-patents-in-response-to-ftc-warning-letters<\/a><\/li>\n\n\n\n<li>Fierce Pharma. (2024). <em>FTC targets Novo&#8217;s Ozempic, others in crackdown on 300-plus &#8216;junk&#8217; patent listings in FDA database<\/em>. <a href=\"https:\/\/www.fiercepharma.com\/pharma\/ftc-targets-novos-ozempic-others-crackdown-300-plus-junk-patent-listings-fda-database\">https:\/\/www.fiercepharma.com\/pharma\/ftc-targets-novos-ozempic-others-crackdown-300-plus-junk-patent-listings-fda-database<\/a><\/li>\n\n\n\n<li>Fierce Pharma. (2025). <em>FTC claims a win as Teva moves to delist hundreds of patents from FDA Orange Book, agency says<\/em>. <a href=\"https:\/\/www.fiercepharma.com\/pharma\/ftc-claims-win-teva-moves-delist-hundreds-patents-fda-orange-book\">https:\/\/www.fiercepharma.com\/pharma\/ftc-claims-win-teva-moves-delist-hundreds-patents-fda-orange-book<\/a><\/li>\n\n\n\n<li>Conrad, R., &amp; Lutter, R. (2019, December). <em>Generic competition and drug prices: New evidence linking greater generic competition and lower generic drug prices<\/em>. U.S. Food and Drug Administration. <a href=\"https:\/\/fda.gov\/media\/133509\/download\">https:\/\/fda.gov\/media\/133509\/download<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>On December 10, 2025, the Federal Trade Commission announced that Teva had asked the FDA to remove more than 200 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":40087,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-40086","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/40086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=40086"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/40086\/revisions"}],"predecessor-version":[{"id":40088,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/40086\/revisions\/40088"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/40087"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=40086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=40086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=40086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}